ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO239

The Impact of Extended Hours Haemodialysis on Quality of Life, Vascular Access, Mortality, and Residual Renal Function: Systematic Review and Meta-Analysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Hull, Katherine Leigh, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
  • March, Daniel Scott, University of Leicester, Leicester, United Kingdom
  • Churchward, Darren R., University of Leicester, Leicester, United Kingdom
  • Graham-Brown, Matthew P.M., University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
  • Burton, James, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Patients with end-stage renal failure on conventional haemodialysis (CHD) experience significant morbidity and mortality. There is increasing evidence that extending weekly haemodialysis (HD) time is associated with improvements in quality of life (QoL), biochemical and cardiovascular parameters, and mortality. However, there is concern that increasing HD duration or frequency accelerates the loss of residual renal function (RRF) and increases vascular access adverse events. This systematic review aims to determine the impact of extended HD in comparison to CHD on QoL, vascular access events, mortality and RRF.


Randomised and non-randomised controlled trials of adult prevalent HD patients comparing extended hours HD (> 12 hours of HD in 1 week) to CHD were eligible. Outcomes of interest were quantitative measures of QoL, vascular access adverse events, all-cause mortality and RRF. Data from randomised and non-randomised trials were pooled separately using a random-effects model.


476 patients from 6 trials were eligible. The number of trials available for meta-analysis varied for each outcome. There was no significant change in QoL when comparing extended HD to CHD (SF-36 PCS standardised mean difference 0.61, 95% CI -0.10 to 1.31, P=0.09, SF-36 MCS standardised mean difference -0.04, 95% CI -0.61 to 0.54, P=0.90). There was no significant change in vascular access adverse events (relative risk ratio 1.25, 95% CI 0.88 to 1.77, P=0.21) or mortality (relative risk ratio 2.29, 95% CI 0.60 to 8.71, P=0.22). RRF was only assessed in one report which demonstrated a potential reduction over 12 months with extended HD, however, RRF was not a pre-specified secondary outcome. All trials had a high risk of bias.


In this systematic review, we demonstrated no significant difference between extended HD and CHD on QoL, adverse vascular access events and mortality. There was only a single trial with data regarding the changes in RRF. The majority of the included trials were either low or very low in quality. This supports the need for further adequately powered randomised controlled trials.


  • Government Support - Non-U.S.